Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosigotifator (ABBV-CLS-7262) in Vanishing White Matter Disease
2023-505704-30-00Phase 2Authorised
- Sponsor
- Calico Life Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of fosigotifator in leukoencephalopathy with vanishing white matter (VWM), sponsored by Calico Life Sciences. Primary endpoints: Adverse events and serious adverse events during the Safety Evaluation Period, Vital signs, ECGs, clinical laboratory tests, and suicidality assessments during the Safety Evaluation Period and 3 more. Planned start Feb 2024; status: authorised.
02
Drugs
fosigotifator
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on 2023-505704-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505704-30-00.